Novel post-amadori inhibitors of advanced glycation reactions

A pharmaceutical composition comprising an amount effective to inhibit the conversion of Amadori compounds to post Amadori advanced glycation endproducts of a compound of the general formula

• 12
• wherein
• R1, R1′, R5, and R5′ are independently selected from the group consisting of (CH2)nX wherein n is between 0 and 6 and X is H, OH, SH, COOH or NH2;
• and mono-, di-, or tri-halogenated C1-6 alkyl, C1-6 alkoxy, or C1-6 alkenyl;
• with the proviso that at least one R1, R1′, R5, and R5′ is selected from the group consisting of OH, SH, and NH2;
• wherein R2, R2′, R4 and R4′ are independently selected from the group consisting of (CH2)nZ, wherein n has the meaning given above and Z is H, OH, SH, COOH, or NH2;
• and mono-, di-, or tri-halogenated C1-6 alkyl, C1-6 alkoxy, or C1-6 alkenyl;
• wherein R3 and R3′ are independently selected from the group consisting of H and mono-, di-, or tri-halogenated C1-6 alkyl;
• wherein R6 and R6′ are (CH2)x, wherein x is between 1 and 6;
• wherein R7 is selected from NH and HOP═O;
• or wherein R6, R6′, and R7 combine to form an aryl group, heteroaryl group, or
• 13
• or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof;
• and a pharmaceutically acceptable carrier.

A pharmaceutical composition comprising an amount effective for treating or preventing an AGE related pathology in a mammal of a compound of the general formula

• 14
• wherein
• R1, R1′, R5, and R5′ are independently selected from the group consisting of (CH2)nX wherein n is between 0 and 6 and X is H, OH, SH, COOH or NH2;
• and mono-, di-, or tri-halogenated C1-6 alkyl, C1-6 alkoxy, or C1-6 alkenyl;
• with the proviso that at least one R1, R1′, R5, and R5′ is selected from the group consisting of OH, SH, and NH2;
• wherein R2, R2′, R4 and R4′ are independently selected from the group consisting of (CH2)nZ, wherein n has the meaning given above and Z is H, OH, SH, COOH, or NH2;
• and mono-, di-, or tri-halogenated C1-6 alkyl, C1-6 alkoxy, or C1-6 alkenyl;
• wherein R3 and R3′ are independently selected from the group consisting of H and mono-, di-, or tri-halogenated C1-6 alkyl;
• wherein R6 and R6′ are (CH2)x, wherein x is between 1 and 6;
• wherein R7 is selected from NH and HOP═O;
• or wherein R6, R6′, and R7 combine to form an aryl group, heteroaryl group, or
• 15
• or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof;
• and a pharmaceutically acceptable carrier.